Eric Kmiec is recognized as a pioneer in the field of gene editing. He is the Founder and Director of the gene editing Institute at the Helen F Graham cancer center with faculty appointments at the University of Delaware and the Wistar Institute. His laboratory has been supported by the National Institutes of Health, the National Science Foundation and the Bi-national Industrial Research and Development Foundation for over 25 years. A major focus of his laboratory now centers on understanding how best to translate the human gene editing from bench to bedside within the context of a small community cancer center as well as a large health care system. Dr. Kmiec has been instrumental in developing a task force assembled to evaluate the true potential of human gene editing for integration into a large healthcare system. He has done this by establishing a Gene Editing 360 group within which topics involving the diversity of care for gene therapy and gene editing, ethical administration of gene editing and the economic impact of introducing novel treatments into the healthcare industry. He has authored 160 peer-reviewed publications as primary or senior author and sits on a number of editorial boards and scientific study and grant review sections. Dr. Kmiec has 15 issued patents and has received numerous service medals and awards including the Genome Canada Lectureship, the Proudford Research Award in Sickle Cell Disease and the PICC Life Sciences Innovator Award. He has also been named as an Honorary Commander at Dover Air Force Base and as an Eminent Scholar at Marshall University. Dr Kmiec has been the primary thesis adviser for 15 PhD doctoral students and many postdoctoral fellows. He has also founded two biotechnology companies in acts as a outside adviser for pharmaceutical and biomedical research entities.